Low-Dose rituximab shows promise for blood disorder

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-60 years old; * Diagnosis of primary immune thrombocytopenia according to the guidelines of American Society of Hematology for at least 3 months before inclusion; * Platelet count \<30×109/L (measured at least twice during the screening, with at least a 1-week interval); * Failed or dependent on or relapsed after previous treatment with glucocorticoid; * If on glucocorticoid maintenance therapy, dose ≤0.5 mg/kg prednisone or equivalent and stabilised for at least 4 weeks; * Drugs such as azathioprine, danazol, cyclosporine A, tacrolimus, and sirolimus stopped for at least 4 weeks; * Splenectomy more than 6 months previously; * Previous rescue therapy of ITP (including methylprednisolone, platelet transfusion and IVIG) completed at least 2 weeks before the first administration; * Liver and kidney function (including alanine aminotransferase, aspartate aminotransferase, total bilirubin, serum creatine, urea nitrogen, etc.) less than 1.5 times the upper limit of normal value; * Eastern Cooperative Oncology Group performance status ≤2; * Cardiac function classification (New York Heart Association) ≤2; * Understand the research procedure and voluntarily sign a written informed consent form. Exclusion Criteria: * Patients with secondary thrombocytopenia (including myelodysplastic syndrome, aplastic anemia, common variant immunodeficiency disease, hereditary thrombocytopenia, drug-induced thrombocytopenia, pseudothrombocytopenia, connective tissue disease secondary thrombocytopenia, thrombocytopenia after liver disease, etc.); * Previous treatment of RTX or allergic to RTX; * Uncontrollable primary diseases of important organs (including malignant tumor, liver failure, heart failure, kidney failure and other diseases); * HIV-positive status; * Active infection including hepatitis B (HBV), hepatitis C (HCV) and other viral antigens or DNA, RNA positive; cytomegalovirus, Epstein-Barr virus, syphilis chronic or active infection. If HBV core antibodies are positive, HBV-DNA testing is required. * Extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc. * Heart disease or arrhythmia need treatment, or poorly controlled hypertension; * Thrombotic diseases including pulmonary embolism, thrombosis, atherosclerosis, etc.; * Previously allogeneic stem cell transplantation or organ transplantation; * Mental disorders who are unable to obtain informed consent normally and participate in trials and follow-up; * Symptoms of toxicity from pre-trial treatment have not resolved; * Other severe conditions that may limit participation in the trial (e.g., diabetes; severe cardiac insufficiency; myocardial infarction or unstable arrhythmia or unstable angina within the last 6 months; gastric ulcer; active autoimmune diseases, etc.); * Sepsis or other irregular bleeding; * Taking antiplatelet drugs; * pregnancy, suspected pregnancy (urine human chorionic gonadotropin positive during screening) or lactation.